Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00035152
Status:
COMPLETED
Last Update Posted:
2016-09-19
First Post:
2002-05-02
Brief Title:
Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Multicenter Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly TaxolPaclitaxel and CarboplatinParaplatin Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks Followed by Weekly Taxol
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small cell lung carcinoma
This study compares treatment with Taxolcarboplatin given every 3 weeks to a schedule where it is given weekly
The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma
This study compares treatment with Taxolcarboplatin given every 3 weeks to a schedule where it is given weekly
The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None